AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3080044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (G)
Number of subjects: 62
Study 3080044 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (PEN)
Number of subjects: 62
Study 30143550 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus MM
Number of subjects: 60
Study 30143550 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 26782247 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen via a facemask at a constant flow rate of 3 l/min (O2 group)
Number of subjects: 30
Study 26782247 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen (Air group)
Number of subjects: 30
Study 25531191 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelox®R
Number of subjects: 50
Study 25531191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22563468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (2 µg/kg)
Number of subjects: 33
Study 22563468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 33
Study 20478580 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203
Study 20478580 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 203
Study 20478580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance with antibiotics only for symptomatic urinary tract infection
Number of subjects: 203
Study 18703473 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation using organs from donors who died from cardiocirculatory causes
Number of subjects: 3
Study 18703473 — intervention group
Group type: COMPARATOR
Intervention: Standard organ donation
Number of subjects: 3
Study 17128844 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week amphotericin B (AmB1)
Number of subjects: 57
Study 17128844 — intervention group
Group type: COMPARATOR
Intervention: Two-week amphotericin B (AmB2)
Number of subjects: 57
Study 17128844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 57
Study 12923824 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus nizatidine
Number of subjects: 35
Study 12923824 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 35
Study 10846305 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 42
Study 10846305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42
Study 10846305 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 42
Study 9288517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold antegrade St. Thomas II cardioplegic solution
Number of subjects: 30
Study 9288517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretschneider cardioplegic solution
Number of subjects: 30
Study 9288517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamburg cardioplegic solution
Number of subjects: 30
Study 9288517 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline samples)
Number of subjects: 30
Study 8385552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol HCL 100 mg (Group A)
Number of subjects: 90
Study 8385552 — intervention group
Group type: COMPARATOR
Intervention: Multi-vita (Group B)
Number of subjects: 90
Study 8385552 — intervention group
Group type: COMPARATOR
Intervention: Analgesic containing aspirin 399 mg and codeine phosphate 15 mg (Group C)
Number of subjects: 90
Study 3943275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of alanine
Number of subjects: 0
Study 3943275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of alanine
Number of subjects: 0
Study 31617873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 100
Study 31617873 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study 30905021 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125
Study 30905021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 28963592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with 1.2% betaine supplementation
Number of subjects: 5
Study 28963592 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 5
Study 26049730 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous vagus nerve stimulation (tVNS) for 30 minutes (0-10 V, 1 ms, 20 Hz) starting 10 minutes before LPS administration (2 ng kg(-1) Escherichia coli lipopolysaccharide)
Number of subjects: 20
Study 26049730 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (no electrical stimulation)
Number of subjects: 20
Study 23319644 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity strength (FCS) during resting state
Number of subjects: 0
Study 23319644 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity strength (FCS) during working-memory task
Number of subjects: 0
Study 23319644 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-induced changes of FCS and rCBF in the lateral-parietal lobe
Number of subjects: 0
Study 23319644 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF/FCS ratio
Number of subjects: 0
Study 21746696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (interactive educational workshop, portfolio of practical clinical genetics tools, Gene Messenger)
Number of subjects: 125
Study 21746696 — intervention group
Group type: COMPARATOR
Intervention: Control (standard practice)
Number of subjects: 125
Study 19455196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (12 weekly sessions over 3 months)
Number of subjects: 85
Study 19455196 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment in dialysis unit
Number of subjects: 85
Study 16980747 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha (40,000 IU weekly)
Number of subjects: 61
Study 16980747 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (RBV dose reduction from 1000/1200 to 800/600 mg)
Number of subjects: 61
Study 15531693 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich diet (38% fat - 20% SFA, 12% MUFA, 47% CHO)
Number of subjects: 55
Study 15531693 — intervention group
Group type: COMPARATOR
Intervention: CHO-rich diet (30% fat - <10% SFA, 12% MUFA, 55% CHO)
Number of subjects: 55
Study 15531693 — intervention group
Group type: COMPARATOR
Intervention: MUFA-rich diet (38% fat - <10% SFA, 22% MUFA, 47% CHO)
Number of subjects: 55
Study 15531693 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich diet
Number of subjects: 55
Study 15531693 — intervention group
Group type: COMPARATOR
Intervention: Change from SFA to CHO diet
Number of subjects: 55
Study 11701734 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human LH (50 IU)
Number of subjects: 15
Study 11701734 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 9404792 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 48
Study 9404792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 48
Study 9404792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8517684 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast transfer (55 million viable, purified normal myoblasts injected at 55 sites)
Number of subjects: 8
Study 8517684 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast transfer
Number of subjects: 8
Study 8517684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 3553135 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftizoxime (2-4 g every 8 h)
Number of subjects: 135
Study 3553135 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotaxime (1-2 g every 4 h)
Number of subjects: 135
Study 3553135 — intervention group
Group type: EXPERIMENTAL
Intervention: latamoxef (2-4 g every 8 h)
Number of subjects: 135
Study 29106812 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 20
Study 29106812 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic carbohydrate (CHO)
Number of subjects: 20
Study 27183109 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 27183109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg with either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Number of subjects: 513
Study 24868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination treatment
Number of subjects: 513
Study 22871307 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflatable soft tissue expander
Number of subjects: 20
Study 22871307 — intervention group
Group type: COMPARATOR
Intervention: Mandibular ramus bone block graft
Number of subjects: 20
Study 20199139 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg once daily for 16 days, then tapered to 5 mg for 14 days
Number of subjects: 34
Study 20199139 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg once daily for 16 days, then tapered to 30 mg for 14 days
Number of subjects: 34
Study 18627340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost (dosed each evening)
Number of subjects: 29
Study 18627340 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/timolol-fixed combination (DTFC, twice-daily)
Number of subjects: 29
Study 18627340 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/timolol-fixed combination (DTFC)
Number of subjects: 29
Study 18627340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 29
Study 15969661 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg daily in addition to fluticasone 200μg
Number of subjects: 1490
Study 15969661 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50μg twice daily in addition to fluticasone 200μg
Number of subjects: 1490
Study 15969661 — intervention group
Group type: COMPARATOR
Intervention: Asthma patients without concomitant AR (Control)
Number of subjects: 1490
Study 12121563 — intervention group
Group type: COMPARATOR
Intervention: Low-dose meglumine antimoniate (MA) at 60 mg/kg/day for 20 days
Number of subjects: 72
Study 12121563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of allopurinol (AL) at 20 mg/kg/day plus low-dose MA at 30 mg/kg/day for 20 days
Number of subjects: 72
Study 10626305 — intervention group
Group type: EXPERIMENTAL
Intervention: modern active physiotherapy
Number of subjects: 148
Study 10626305 — intervention group
Group type: EXPERIMENTAL
Intervention: muscle reconditioning on training devices
Number of subjects: 148
Study 10626305 — intervention group
Group type: EXPERIMENTAL
Intervention: low-impact aerobics
Number of subjects: 148
Study 7732340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (500 mg, twice daily)
Number of subjects: 79
Study 7732340 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone foam (178 mg, twice daily)
Number of subjects: 79
Study 7732340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories
Number of subjects: 79
Study 1904091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent feeding (5 minutes)
Number of subjects: 11
Study 1904091 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding (2 to 3 hours)
Number of subjects: 11
Study 1904091 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intermittent vs continuous feeding
Number of subjects: 11
Study 6972028 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Number of subjects: 30
Study 6972028 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 30
Study 6972028 — intervention group
Group type: COMPARATOR
Intervention: Neck collar
Number of subjects: 30
Study 30606239 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVE LiFE program (n = 25)
Number of subjects: 40
Study 30606239 — intervention group
Group type: COMPARATOR
Intervention: Written fall risk assessment (n = 12)
Number of subjects: 40
Study 29551560 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice a day)
Number of subjects: 49
Study 29551560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27358435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3320
Study 27358435 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3320
Study 24162081 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 338
Study 24162081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 23254273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/d
Number of subjects: 41
Study 23254273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23254273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses)
Number of subjects: 41
Study 21050060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with SLITone Alternaria, one vial per day for 3 years (n = 34)
Number of subjects: 52
Study 21050060 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 52
Study 21050060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 52
Study 21050060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 17577644 — intervention group
Group type: EXPERIMENTAL
Intervention: NP101 (iontophoretic sumatriptan patch)
Number of subjects: 100
Study 17577644 — intervention group
Group type: EXPERIMENTAL
Intervention: NP101 (iontophoretic sumatriptan patch) delivering 6 and 12 mA per h
Number of subjects: 100
Study 17577644 — intervention group
Group type: COMPARATOR
Intervention: 6 mg subcutaneous injection of sumatriptan
Number of subjects: 100
Study 17577644 — intervention group
Group type: COMPARATOR
Intervention: 50 mg oral tablet of sumatriptan succinate
Number of subjects: 100
Study 15734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Premelle 2.5 mg (0.625 mg conjugated estrogen + 2.5 mg medroxyprogestorone)
Number of subjects: 375
Study 15734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Kliogest (2 mg estradiol + 1 mg norethisterone)
Number of subjects: 375
Study 15734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Livial (2.5 mg tibolone)
Number of subjects: 375
Study 15734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial polyp recurrence
Number of subjects: 375
Study 12769416 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10084579 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP21 genotyping
Number of subjects: 653
Study 10084579 — intervention group
Group type: EXPERIMENTAL
Intervention: Guthrie cards
Number of subjects: 653
Study 7582401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day)
Number of subjects: 42
Study 7582401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (30 mg/day) after niceritrol (750 mg/day)
Number of subjects: 42
Study 7582401 — intervention group
Group type: COMPARATOR
Intervention: Niceritrol (750 mg/day)
Number of subjects: 42
Study 7582401 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol (750 mg/day) after fluvastatin (30 mg/day)
Number of subjects: 42
Study 7582401 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol (750 mg/day) and Fluvastatin (30 mg/day)
Number of subjects: 42
Study 2210218 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate enema
Number of subjects: 100
Study 2210218 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin enema
Number of subjects: 100
Study 2210218 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 100
Study 508974 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen (heliox) mixture
Number of subjects: 24
Study 508974 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 24
Study 31670546 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological performance assessments (global deficit score, executive-functioning domain, processing-speed domain)
Number of subjects: 50
Study 31670546 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 50
Study 31670546 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing-speed performance
Number of subjects: 50
Study 29702271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine-N-Butylbromide (HBB) 20 mg
Number of subjects: 146
Study 29702271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 29029673 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed Acceptance
Number of subjects: 193
Study 29029673 — intervention group
Group type: COMPARATOR
Intervention: Instructed Suppression
Number of subjects: 193
Study 26094656 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 83
Study 26094656 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 83
Study 24207160 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRNSTAT (Physician-Nurse Supplementary Team At Triage)
Number of subjects: 6336
Study 24207160 — intervention group
Group type: COMPARATOR
Intervention: Nurse-only triage (Control)
Number of subjects: 6336
Study 19945757 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline significant IADL disability
Number of subjects: 1164
Study 19945757 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline significant ADL disability
Number of subjects: 1164
Study 19945757 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall functional status
Number of subjects: 1164
Study 19945757 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of functional decline
Number of subjects: 1164
Study 18791718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel (175 mg/m2, 15 min intravenous infusion)
Number of subjects: 35
Study 18791718 — intervention group
Group type: COMPARATOR
Intervention: Taxol (175 mg/m2, 3 h intravenous infusion)
Number of subjects: 35
Study 17458428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco skin prick test
Number of subjects: 180
Study 17458428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial challenge with tobacco
Number of subjects: 180
Study 17458428 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed bronchial and patch response
Number of subjects: 180
Study 17458428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco IgE response (EAST)
Number of subjects: 180
Study 17458428 — intervention group
Group type: EXPERIMENTAL
Intervention: EAST inhibition
Number of subjects: 180
Study 14726744 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (Ig) therapy
Number of subjects: 45
Study 14726744 — intervention group
Group type: COMPARATOR
Intervention: No Immunoglobulin (Ig) therapy
Number of subjects: 45
Study 15831513 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fentanyl (100 microg)
Number of subjects: 202
Study 15831513 — intervention group
Group type: COMPARATOR
Intervention: i.c. fentanyl (100 microg)
Number of subjects: 202
Study 10355660 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 6.0
Number of subjects: 46
Study 10355660 — intervention group
Group type: COMPARATOR
Intervention: Version 4.7
Number of subjects: 46
Study 8571936 — intervention group
Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (150 x 10(4) IU: 3 MIU) administered three times a week
Number of subjects: 50
Study 8571936 — intervention group
Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (300 x 10(4) IU: 3 MIU) administered three times a week
Number of subjects: 50
Study 8571936 — intervention group
Group type: EXPERIMENTAL
Intervention: rh IFN alpha‐2b (3 MIU) administered once a week for 8 weeks
Number of subjects: 50
Study 8571936 — intervention group
Group type: EXPERIMENTAL
Intervention: Any administration schedule of rh IFN alpha‐2b
Number of subjects: 50
Study 8571936 — intervention group
Group type: EXPERIMENTAL
Intervention: Once a week administration schedule of rh IFN alpha‐2b
Number of subjects: 50
Study 2018005 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxypropafenone (300 mg, single oral dose)
Number of subjects: 6
Study 2018005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7036279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-cyclophosphamide (AC) chemotherapy
Number of subjects: 138
Study 7036279 — intervention group
Group type: EXPERIMENTAL
Intervention: AC chemotherapy plus comprehensive regional radiotherapy
Number of subjects: 138
Study 7036279 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 138
Study 31742488 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-mobilization with movement (S-MWM)
Number of subjects: 38
Study 31742488 — intervention group
Group type: COMPARATOR
Intervention: Calf muscle stretching (CMS)
Number of subjects: 38
Study 31095313 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH) 0.08 g/kg BW
Number of subjects: 10
Study 31095313 — intervention group
Group type: COMPARATOR
Intervention: Intact Whey Protein (WHEY)
Number of subjects: 10
Study 28969952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft with preserved insertions (technique 1)
Number of subjects: 110
Study 28969952 — intervention group
Group type: COMPARATOR
Intervention: Free hamstring tendon autograft (technique 2)
Number of subjects: 110
Study 26075373 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT (negative pressure wound therapy)
Number of subjects: 16
Study 26075373 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressings
Number of subjects: 16
Study 23463811 — intervention group
Group type: EXPERIMENTAL
Intervention: HBPM
Number of subjects: 348
Study 23463811 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 348
Study 20883991 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 40
Study 20883991 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone analogue (GnRH-a; gosareline acetate; Zoladex)
Number of subjects: 40